Trial with Danish coronavirus therapy is prioritized in the UK

Union Therapeutics' trial with the drug niclosamide for treating Covid-19 patents with kidney diseases has gained further support from UK authorities.

Photo: Union Therapeutics / PR

The National Institute for Health Research (NIHR) in the UK has given special status to a study from Danish biotech company Union Therapeutics, according to a press release from the company.

Union Therapeutics' Protect-V trial tests the firm's niclosamide nasal spray on patients with kidney diseases having Covid-19.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs